• Dendreon Corp., of Seattle, started enrolling patients in an open-label European study with Provenge (sipuleucel-T). The study is being conducted in European men with metastatic castrate-resistant prostate cancer to describe product-release parameters and report on safety in a European population. The study may enroll up to 45 patients in four sites across the EU. Provenge was approved in the U.S. in 2010. (See BioWorld Today, April 30, 2010.)

• MicroDose Therapeutx Inc., of Monmouth Junction, N.J., completed its third and final Phase I study with its inhaled antiviral fusion inhibitor, MDT-637, for the treatment of respiratory syncytial virus. MicroDose presented the data from all three studies at the 8th Annual International Respiratory Syncytial Virus Symposium in Santa Fe, N.M.

• Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., opened enrollment in a Phase II study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing drug to malignant cells. Phase I data will be presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 6-9 in Dublin, Ireland.

• XOMA Corp., of Berkeley, Calif., said its partner Servier, of Paris, received authorization to initiate the Servier-sponsored Behçet's uveitis Phase III trial in several European countries. The objective of the study is to evaluate the efficacy of gevokizumab as compared to placebo on top of current standard of care (immunosuppressive therapy and oral corticosteroids) in reducing the risk of Behçet's disease uveitis exacerbations and to assess the safety of gevokizumab. In the U.S., the drug entered Phase III testing in June. (See BioWorld Today, June 28, 2012.)